INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 421m ago
HOUSE PTR21m ago
SEC 13F21m ago
ROBINHOOD CHAIN21m ago
Public company

NBPNovaBridge Biosciences

CIK 0001778016

EDGAR filingsOpen in network
Disclosed transactions30
Buys / sells0 / 6
Max Insider Score42
Connections7with evidence

NBP · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
WY
Woo Ian YingDirector
NBPNovaBridge Biosciences
Option exercise
M—
13.3K sh
Oct 15, 2026Oct 19, 2026
traded Oct 15, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Woo Ian YingDirector · Oct 19, 2026
  • ← Insider ofevidence
    Lenz Robert A.Director · Aug 25, 2026
  • ← Insider ofevidence
    Fu WeiDirector · Jun 30, 2026
21
WY
Woo Ian YingDirector
NBPNovaBridge Biosciences
Option exercise
M
—
5,770 sh
Oct 15, 2026
Oct 19, 2026
traded Oct 15, 2026
+4d
SEC FORM 4

Evidence

9
DA
Dennis Phillip AndrewChief Medical Officer
NBPNovaBridge Biosciences
Option exercise
M—
23.7K sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

9
DA
Dennis Phillip AndrewChief Medical Officer
NBPNovaBridge Biosciences
Option exercise
M—
10.3K sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

22
DA
Dennis Phillip AndrewChief Medical Officer
NBPNovaBridge Biosciences
Open-market sale
SELL$5,828
8,209 sh
Sep 18, 2026Sep 21, 2026
traded Sep 18, 2026
+3dSEC FORM 4

Evidence

42
CW
Cao Sean WuxiongChief Bus. Development Officer
NBPNovaBridge Biosciences
Open-market sale
SELL$80K
108.0K sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

27
CW
Cao Sean WuxiongChief Bus. Development Officer
NBPNovaBridge Biosciences
Option exercise
M—
235.1K sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

27
CW
Cao Sean WuxiongChief Bus. Development Officer
NBPNovaBridge Biosciences
Option exercise
M—
45.3K sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

23
CW
Cao Sean WuxiongChief Bus. Development Officer
NBPNovaBridge Biosciences
Option exercise
M—
102.2K sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

23
CW
Cao Sean WuxiongChief Bus. Development Officer
NBPNovaBridge Biosciences
Option exercise
M—
104.2K sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

9
XC
Xu Cong ClaireEVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
4,079 sh
Aug 30, 2026Sep 1, 2026
traded Aug 30, 2026
+2dSEC FORM 4

Evidence

5
XC
Xu Cong ClaireEVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
9,382 sh
Aug 30, 2026Sep 1, 2026
traded Aug 30, 2026
+2dSEC FORM 4

Evidence

22
XC
Xu Cong ClaireEVP, Clinical Development
NBPNovaBridge Biosciences
Open-market sale
SELL$2,593
3,282 sh
Aug 31, 2026Sep 1, 2026
traded Aug 31, 2026
+1dSEC FORM 4

Evidence

9
LA
Lenz Robert A.Director
NBPNovaBridge Biosciences
Option exercise
M—
17.2K sh
Aug 22, 2026Aug 25, 2026
traded Aug 22, 2026
+3dSEC FORM 4

Evidence

21
LA
Lenz Robert A.Director
NBPNovaBridge Biosciences
Option exercise
M—
7,486 sh
Aug 22, 2026Aug 25, 2026
traded Aug 22, 2026
+3dSEC FORM 4

Evidence

17
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Open-market sale
SELL$3,992
4,485 sh
Jul 6, 2026Jul 7, 2026
traded Jul 6, 2026
+1dSEC FORM 4

Evidence

5
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
12.4K sh
Jul 4, 2026Jul 7, 2026
traded Jul 4, 2026
+3dSEC FORM 4

Evidence

5
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
5,405 sh
Jul 4, 2026Jul 7, 2026
traded Jul 4, 2026
+3dSEC FORM 4

Evidence

9
FW
Fu WeiDirector
NBPNovaBridge Biosciences
Grant or award
A—
1.01M sh
Jun 29, 2026Jun 30, 2026
traded Jun 29, 2026
+1dSEC FORM 4

Evidence

9
FW
Fu WeiDirector
NBPNovaBridge Biosciences
Grant or award
A—
725.1K sh
Jun 29, 2026Jun 30, 2026
traded Jun 29, 2026
+1dSEC FORM 4

Evidence

9
FW
Fu WeiDirector
NBPNovaBridge Biosciences
Grant or award
A—
1.09M sh
Jun 29, 2026Jun 30, 2026
traded Jun 29, 2026
+1dSEC FORM 4

Evidence

9
FW
Fu WeiDirector
NBPNovaBridge Biosciences
Grant or award
A—
1.09M sh
Jun 29, 2026Jun 30, 2026
traded Jun 29, 2026
+1dSEC FORM 4

Evidence

9
CW
Cao Sean WuxiongDirector, Chief Bus. Development Officer
NBPNovaBridge Biosciences
Grant or award
A—
181.3K sh
Jun 22, 2026Jun 24, 2026
traded Jun 22, 2026
+2dSEC FORM 4

Evidence

9
CW
Cao Sean WuxiongDirector, Chief Bus. Development Officer
NBPNovaBridge Biosciences
Grant or award
A—
181.3K sh
Jun 22, 2026Jun 24, 2026
traded Jun 22, 2026
+2dSEC FORM 4

Evidence

19
DA
Dennis Phillip AndrewChief Medical Officer
NBPNovaBridge Biosciences
Option exercise
M—
23.7K sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

19
DA
Dennis Phillip AndrewChief Medical Officer
NBPNovaBridge Biosciences
Option exercise
M—
10.3K sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

25
DA
Dennis Phillip AndrewChief Medical Officer
NBPNovaBridge Biosciences
Open-market sale
SELL$5,606
8,494 sh
Jun 18, 2026Jun 22, 2026
traded Jun 18, 2026
+4dSEC FORM 4

Evidence

13
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
4,079 sh
May 30, 2026Jun 2, 2026
traded May 30, 2026
+3dSEC FORM 4

Evidence

21
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Open-market sale
SELL$14K
3,494 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

9
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
9,382 sh
May 30, 2026Jun 2, 2026
traded May 30, 2026
+3dSEC FORM 4

Evidence

← Insider ofevidence
Cao Sean Wuxiong
Director, Chief Bus. Development Officer · Jun 24, 2026
  • ← Insider ofevidence
    Dennis Phillip AndrewChief Medical Officer · Jun 22, 2026
  • ← Insider ofevidence
    Xu Cong ClaireSVP, Clinical Development · Jun 2, 2026